RECRUITING

Study of CHS-114 in Participants With Advanced Solid Tumors

Talk to us

Conditions

Advanced Solid TumorHead and Neck Squamous Cell Carcinomametastatic solid tumorsadvanced solid tumorsPhase 1SRF114CCR8safetyefficacyimmunotherapycancerimmuno-oncologyCHS-114

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Official Title

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Quick Facts

Study Start:2022-12-15
Study Completion:2026-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05635643

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Hillary O'Kelly
CONTACT
800-794-5434
hokelly@coherus.com
MD at Coherus, MD
CONTACT
1-800-794-5434

Principal Investigator

Koho Izuka, MD
STUDY_DIRECTOR
Coherus BioSciences

Study Locations (Sites)

Stanford Cancer Center
Palo Alto, California, 94305
United States
SCRI Lake Nona DDU (FL Cancer Specialists)
Orlando, Florida, 32827
United States
Emory Winship Cancer Institute
Atlanta, Georgia, 30308
United States
University of Louisville
Louisville, Kentucky, 40202
United States
University of Michigan
Ann Arbor, Michigan, 48104
United States
Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center
Detroit, Michigan, 48201
United States
Washington University
Saint Louis, Missouri, 63110
United States
University of Cincinnati
Cincinnati, Ohio, 45219
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203
United States
START- San Antonio
San Antonio, Texas, 78229
United States
START Mountain
West Valley City, Utah, 84119
United States
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Coherus Biosciences, Inc.

  • Koho Izuka, MD, STUDY_DIRECTOR, Coherus BioSciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-15
Study Completion Date2026-02

Study Record Updates

Study Start Date2022-12-15
Study Completion Date2026-02

Terms related to this study

Keywords Provided by Researchers

  • metastatic solid tumors
  • advanced solid tumors
  • Phase 1
  • SRF114
  • CCR8
  • safety
  • efficacy
  • immunotherapy
  • cancer
  • immuno-oncology
  • CHS-114

Additional Relevant MeSH Terms

  • Advanced Solid Tumor
  • Head and Neck Squamous Cell Carcinoma